Abstract: Inhibitors of IL-22 are disclosed as well as pharmaceutical compositions and methods of using same. The inhibitors include IL-22 antibodies and are useful for treating inflammatory disorders.

Abstract: A siderail assembly 40 for a bed 20 includes a link P pivotably connectable to a bed frame at a joint PF and to a rail at a joint PR. The link P has at least one reaction surface 64, 66. The assembly also includes a link R having a rail end 78 and a common end 80. The rail end of link R is pivotably connected to the rail at a joint RR. The assembly also includes a link Q having a frame end 72 and a common end 74. The frame end of link Q is pivotably connected to the frame at a joint QF. The common ends of link Q and link R are pivotably connected to each other at a joint A constrained to move substantially parallel to the reaction surface.

Abstract: Inhibitors of IL-22 are disclosed as well as pharmaceutical compositions and methods of using same. The inhibitors include IL-22 antibodies and are useful for treating inflammatory disorders.

Abstract: The present invention provides isolated and purified polynucleotides and polypeptides related to the IL-17F signaling pathway. The invention also provides antibodies to IL-17F homodimers and IL-17A/IL-17F heterodimers, and methods of isolating and purifying members of the IL-17 family, including IL-17A/IL-17F heterodimers, from a natural source. The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating and/or preventing disorders related to IL-17F signaling, i.e., IL-17F-associated disorders, including, but not limited to, inflammatory disorders, such as autoimmune diseases (e.g., arthritis (including rheumatoid arthritis), psoriasis, systemic lupus erythematosus, and multiple sclerosis), respiratory diseases (e.g., COPD, cystic fibrosis, asthma, allergy), transplant rejection (including solid organ transplant rejection), and inflammatory bowel diseases or disorders (IBDs, e.g., ulcerative colitis, Crohn's disease).

Abstract: A person support apparatus comprises a lower frame, a support, and an upper frame. The support is coupled to the lower frame. The upper frame has a head section and a foot section and defines a longitudinal axis passing through the head section and the foot section and a lateral axis substantially perpendicular to the longitudinal axis. The upper frame includes a tilt mechanism pivotably coupling the upper frame to the support. The tilt mechanism includes a base and a rocker nested within the base. The base and the rocker are pivotable with respect to one another about a pivot axis that passes through the base and the rocker and is substantially parallel the longitudinal axis. The upper frame is pivotable about the pivot axis with respect to the lower frame.

Abstract: Inhibitors of IL-22 are disclosed as well as pharmaceutical compositions and methods of using same. The inhibitors include IL-22 antibodies and are useful for treating inflammatory disorders.

Abstract: Novel human GIL-19/AE289 protein is disclosed which shows a high degree of homology to interleukin-10 (IL-10). Polynucleotides encoding such protein are also enclosed.

Abstract: Novel human GIL-19/AE289 protein is disclosed which shows a high degree of homology to interleukin-10 (IL-10). Polynucleotides encoding such protein are also enclosed.

Abstract: The present invention provides isolated and purified polynucleotides and polypeptides related to the IL-17F signaling pathway. The invention also provides antibodies to IL-17F homodimers and IL-17A/IL-17F heterodimers, and methods of isolating and purifying members of the IL-17 family, including IL-17A/IL-17F heterodimers, from a natural source. The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating and/or preventing disorders related to IL-17F signaling, i.e., IL-17F-associated disorders, including, but not limited to, inflammatory disorders, such as autoimmune diseases (e.g., arthritis (including rheumatoid arthritis), psoriasis, systemic lupus erythematosus, and multiple sclerosis), respiratory diseases (e.g., COPD, cystic fibrosis, asthma, allergy), transplant rejection (including solid organ transplant rejection), and inflammatory bowel diseases or disorders (IBDs, e.g., ulcerative colitis, Crohn's disease).

Abstract: A system for a 3-D Phenomenoscope to view 3-dimensional special effects in motion pictures, and a method by which ordinary 2-dimensional motion pictures can be viewed as a 3-dimensionsal experience are disclosed. It provides (a) a 3-D Phenomenoscope with right and left lenses, where the degree of darkness of the right and left lenses can be individually controlled; (b) a digital photo sensors that can capture the viewed motion picture as successive images and convert the captured frames to digital images for processing; (c) a computer processor and a computer program to process the successive images and identify lateral motion synchronization events, and (d) a control unit to provide individual control for the light-reduction or darkening of the right or left lens based on the identified synchronization events. These system and method allow any motion picture to be viewed with the visual effect of 3-dimensions.

Abstract: Polynucleotides encoding human CTLA-8 and related proteins are disclosed. Human CTLA-8 proteins and methods for their production are also disclosed. Methods of treatment using human CTLA-8 proteins, rat CTLA-8 proteins and herpesvirus herpes CTLA-8 proteins are also provided.

Abstract: Novel human GIL-19/AE289 protein is disclosed which shows a high degree of homology to interleukin-10 (IL-10). Polynucleotides encoding such protein are also enclosed.

Abstract: Pulfrich Filter Spectacles to view a 2-dimensional motion picture with 3-dimensional visual effects are disclosed. A method for synchronizing the Puifrich filter spectacles and a method of displaying 2-dimensional motion pictures as 3-dimensional pictures using the spectacles are also disclosed. The Puifrich spectacles and its synchronizing method and displaying method will allow almost any motion picture to be viewed effortlessly by the viewer with the visual effect of 3-dimensions.

Abstract: Novel polynucleotides and the proteins encoded thereby are disclosed.

Abstract: Novel polypeptides of human megakaryocyte stimulating factors (MSFs). Pharmaceutical compositions containing same, and methods for their preparation and use are provided.

Abstract: An equalizer/mixer receives an input signal from a musical source and Equalizes the input signal based on the musical source using equalization parameters Associated with the musical source. User-adjustable equalization controls may be Applied where the equalization parameters defining the controls are associated with the Musical source.

Abstract: Novel polynucleotides and the proteins encoded thereby are disclosed.

Abstract: This invention directs to a video/motion picture displaying apparatus for viewing via 3D spectacles with an internal 3D synchronizing unit including an image capturing means, a synchronizing means to identify synchronization events according to a set of synchronization rules, and a transmitting unit. It further directs to a 2D video/motion picture embedded with synchronizing signals produced with the same synchronization rules. The invention also discloses a 3D synchronizing signal composing/embedding device for embedding synchronizing signals to a 2D video/motion picture including a data capturing means, a converting means, a synchronizing means and a composing means or an embedding means. It also teaches a related 3D control device configured to acquire and utilize the embedded synchronizing signals to control the transmission of light of the 3D spectacles.

Abstract: Novel human GIL-19/AE289 protein is disclosed which shows a high degree of homology to interleukin-10 (IL-10). Polynucleotides encoding such protein are also enclosed.

Abstract: A sliding door assembly includes a sliding door that is slidingly mounted to a top track via one or more top guide assemblies. The sliding door is also slidingly mounted to a bottom track. Each top guide assembly includes a top guide wheel that rotationally mounts to the top guide assembly and engages the top track to guide the sliding door. The guide wheel rotates relative to the top guide assembly about an axis that extends horizontally in a direction perpendicular to a direction of travel of the sliding door. The guide wheel also movably mounts to the top guide assembly so that the guide wheel moves upwardly and downwardly relative to the top guide assembly and sliding door to correct for any variation in the gap between the top and bottom tracks.